Sign in
Active, not recruitingPhase 2

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

Key facts

Who runs it
SHINKEI Therapeutics, Inc
Where
Albuquerque, Detroit, Durham, Gainesville, Houston, Los Angeles, Milwaukee, Neptune City, Philadelphia, Portland, Sacramento, St Louis, and Tampa, United StatesSee the 13 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
45 people, planned
Started
1 Jun 2024
Ended
Aug 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Amantadine Hydrochloride
  • Placebo
Record updated
15 July 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Age: 18 to 75 years
  • Patients with TBI confirmed by CT scan or MRI
  • Patient have sustained a trauma between 72 hours to 1 week
  • Patient with Abbreviated Injury Score (AIS) ≤ 2
  • Patients must be admitted to an acute care setting no less than 2 days prior to randomization
  • Glasgow Coma Score of 3 to 8, inclusive
  • Patients must be unable to consistently follow commands or to engage in functional communication, as assessed by the score on the CRS-R
  • Patients have at least one reactive pupil
  • Must have a Legally Authorized Representative (LAR) able to provide consent for the trial
  • Patient must have stable vitals ---Intracranial pressure ICP Value is at discretion of investigator), systolic blood pressure (SBP>90 mmHg) partial pressure of oxygen (PaO2 > 60 mmHg)]

Who cannot take part

  • Patients with history of any medical or psychiatric disorder, or any severe concomitant disease that would, in the opinion of the Investigator, interfere with clinical assessment
  • Prior history of status epilepticus
  • Prior treatment with or a sensitivity to amantadine HCl or amantadine
  • Patient has received treatment with an investigational drug, CNS stimulant or dopamine antagonist/agonist within 4 weeks
  • Treatment with a systemic anticholinergic medication within 1 week prior to screening
  • Patient has poorly controlled seizure more than one per month
  • Patient has a history of NYHA Class 3 or Class 4 Congestive Heart Failure within the last 5 years
  • any other clinically significant medical condition as determined by the Investigator, that may unfavorably alter the risk benefit of study participation
  • Patient has screening lab measurements outside the normal range; Absolute neutrophil count (ANC): ≤ 1.5 x 109/L; Hemoglobin ≤ 8 g/dL or active bleeding requiring ongoing transfusions; Platelets ≤ 80 x 109/L or active bleeding requiring ongoing transfusions; Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) or total bilirubin (unless isolated Gilbert's syndrome) ≥ 2x the upper limit of normal (ULN); Estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2
  • Patient has prolonged QT interval
  • Life expectancy of less than 24 hours
  • Patient has any spinal cord injury
  • Patient has a penetrating head injury
  • Patient has bilaterally fixed dilated pupils
  • Females who are nursing, pregnant, or planning to become pregnant

Where in United States

  • University of New Mexico HospitalAlbuquerque, United States
  • Wayne State UniversityDetroit, United States
  • Department of Neurology, Duke University School of MedicineDurham, United States
  • UF Health Heart and Vascular HospitalGainesville, United States
  • McGovern Medical School, University of Texas Health Science CenterHouston, United States
  • Los Angeles General Medical CenterLos Angeles, United States
  • Medical College of WisconsinMilwaukee, United States
  • Hackensack Meridian Health Jersey Shore University Medical CenterNeptune City, United States
  • Penn Presbyterian Medical CenterPhiladelphia, United States
  • Maine Medical CenterPortland, United States
  • UC Davis Medical CenterSacramento, United States
  • Barnes-Jewish HospitalSt Louis, United States
  • Tampa General HospitalTampa, United States

About the trial

What the trial wants to find out

The main goal of this clinical trial is to check if the treatment is safe and well-tolerated. Researchers will compare the MR-301 active drug group with the placebo group to evaluate the safety and tolerability of the drug. Other measurements include assessing the patient's overall outcome, neurological responses, time spent in the intensive care unit, time in the hospital, and mortality. Participants will receive either MR-301 BID IV dosing or a matching placebo for a total of 3 weeks.

The 2 groups in the trial

  • MR-301Existing treatment, for comparison

    On first day, patient will receive MR-301 at 100 mg intravenous infusion BID. On second day, the dose is elevated to 150 mg intravenous infusion BID. On third day, the dose is further elevated to 200 mg intravenous infusion BID and maintained up to Day 21

    Treatment: Amantadine Hydrochloride

  • PlaceboPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Multicenter, Double-blind, Randomized, Placebo Controlled, Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301), in Patients With Severe Traumatic Brain Injury (TBI).
Record updated
15 July 2025